CN110914276A - 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 - Google Patents

用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 Download PDF

Info

Publication number
CN110914276A
CN110914276A CN201880035538.2A CN201880035538A CN110914276A CN 110914276 A CN110914276 A CN 110914276A CN 201880035538 A CN201880035538 A CN 201880035538A CN 110914276 A CN110914276 A CN 110914276A
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
halogenated
alkoxy
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035538.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.麦卡伊
H.帕如赫什
G.米扎尼
A.戴尔维格
J.百克利
G.M.希布雅
J.杜布瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
SiteOne Therapeutics Inc
Original Assignee
Leland Stanford Junior University
SiteOne Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, SiteOne Therapeutics Inc filed Critical Leland Stanford Junior University
Publication of CN110914276A publication Critical patent/CN110914276A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880035538.2A 2017-03-29 2018-03-29 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 Pending CN110914276A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478519P 2017-03-29 2017-03-29
US62/478519 2017-03-29
PCT/US2018/025304 WO2018183782A1 (en) 2017-03-29 2018-03-29 11,13-modified saxitoxins for the treatment of pain

Publications (1)

Publication Number Publication Date
CN110914276A true CN110914276A (zh) 2020-03-24

Family

ID=62002497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880035538.2A Pending CN110914276A (zh) 2017-03-29 2018-03-29 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物

Country Status (5)

Country Link
US (1) US11279706B2 (https=)
EP (1) EP3601290B1 (https=)
JP (1) JP2020515611A (https=)
CN (1) CN110914276A (https=)
WO (1) WO2018183782A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
EP4196482B1 (en) * 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
HRP20260068T1 (hr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256248A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
CN102459273A (zh) * 2009-05-07 2012-05-16 里兰斯坦福初级大学理事会 用于研究、成像以及治疗疼痛的方法和组合物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3957996A (en) 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
EP0857972A1 (en) 1997-01-24 1998-08-12 Tepual, S.A. Immunoassay for the detection and quantitation of toxins causing paralytic shellfish poisoning
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CN1081034C (zh) 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
WO1998043619A2 (en) 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1382443A (zh) 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
CN1194693C (zh) 2002-01-11 2005-03-30 中国科学院海洋研究所 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用
AU2003298837A1 (en) 2002-12-02 2004-06-23 Massachusetts Institute Of Technology Prolonged suppression of electrical activity in excitable tissues
AU2003901897A0 (en) 2003-02-12 2003-05-08 Australian Institute Of Marine Science Conjugate
US20050137177A1 (en) 2003-12-18 2005-06-23 Shafer Steven L. Ester combination local anesthetic
JP2007536269A (ja) 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法
JP2007538010A (ja) 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
RU2277097C1 (ru) 2004-12-27 2006-05-27 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Высокомеченный тритием дигидрохлорид [3h]сакситоксина
CN101513408A (zh) 2008-02-19 2009-08-26 熊平 双胍基嘌呤环类衍生物制备提高抗癌药药效的新应用
WO2010019963A2 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
CN102459273A (zh) * 2009-05-07 2012-05-16 里兰斯坦福初级大学理事会 用于研究、成像以及治疗疼痛的方法和组合物
US20160115173A1 (en) * 2009-05-07 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
史清文等: "海洋天然产物化学研究新进展", 《药学学报》 *

Also Published As

Publication number Publication date
EP3601290B1 (en) 2021-11-24
EP3601290A1 (en) 2020-02-05
US20200102317A1 (en) 2020-04-02
US11279706B2 (en) 2022-03-22
WO2018183782A1 (en) 2018-10-04
JP2020515611A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
CN110914276A (zh) 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
US11834456B2 (en) 11,13-modified saxitoxins for the treatment of pain
EP3860714B1 (en) 11,13-modified saxitoxins for the treatment of pain
EP4196482B1 (en) Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
EP3356370B1 (en) 11,13-modified saxitoxins for the treatment of pain
RU2778455C2 (ru) 11,13-модифицированные сакситоксины для лечения боли
EA051377B1 (ru) Негидратированные кетонные ингибиторы nav1.7 для лечения боли

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200324